Is EFTR or MRK a better dividend investment in 2026?

EFTR currently yields 1000000.00% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: EFTR offers higher current income.

What is the dividend yield difference between EFTR and MRK?

EFTR has a forward dividend yield of 1000000.00% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 999997.24 percentage points.

Home › Compare › EFTR vs MRK

EFTR vs MRK: Dividend Comparison 2026

EFTR yields 1000000.00% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EFTR wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EFTR

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full EFTR calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — EFTR vs MRK

📍 EFTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EFTR	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EFTR + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EFTR pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTR

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, EFTR beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTR + MRK for your $10,000?

EFTR: 50%MRK: 50%

100% MRK50/50100% EFTR

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EFTR

Analyst Ratings

Buy

Consensus: Buy

Price Target

$5.50

+2749900.0% upside vs current

Range: $1.00 — $10.00

Altman Z

-13.6

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTR buys

MRK buys

No recent congressional trades found for EFTR or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEFTRMRK

Forward yield	1000000.00% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.7683925249533696e+36M	$56.8K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$4.7683311610149396e+36M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy
Analyst price target	$5.50	$128.54 ✓

Year-by-year: EFTR vs MRK ($10,000, DRIP)

Year	EFTR Portfolio	EFTR Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$11,206	$366.19	+$100.00M → EFTR
2	$934,786,450,701	$934,679,439,252.34	$12,650	$502.35	+$934786.44M → EFTR
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$14,407	$694.19	+$8165787108.56M → EFTR
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$16,585	$967.82	+$66665884190957.63M → EFTR
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$19,342	$1,363.89	+$508662171058048128.00M → EFTR
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$22,913	$1,947.19	+$3.62723524842849e+21M → EFTR
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$27,662	$2,823.89	+$2.417368115915061e+25M → EFTR
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$34,159	$4,173.35	+$1.5056740286145463e+29M → EFTR
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$43,337	$6,308.80	+$8.764771002818475e+32M → EFTR
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$56,776	$9,798.13	+$4.7683925249533696e+36M → EFTR

EFTR vs MRK: Complete Analysis 2026

EFTR — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Full EFTR Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this EFTR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTR vs SCHD EFTR vs JEPI EFTR vs O EFTR vs KO EFTR vs MAIN EFTR vs JNJ EFTR vs ABBV EFTR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.